A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

NCT07724340 · Recruiting

Last updated 2026-08-27

This clinical trial is testing whether a new medication, AT673, taken together with semaglutide, can help adults with type 2 diabetes and overweight or obesity manage their body weight.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 150 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-06 · est. completion 2027-03

Where 8 sites · United States

What this study is testing ClinicalTrials.gov NCT07724340 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn if AT673 contributes to additional weight loss and glycemic control when given with semaglutide in participants with overweight/obesity and type 2 diabetes. The main questions it aims to answer are: * To compare the effect on body weight of two doses of AT673 once-weekly versus matched placebo when concurrently administered with semaglutide once-weekly * To evaluate the effect of AT673 on glycated hemoglobin (HbA1c) * To compare the safety and tolerability of AT673 versus matched placebo when concurrently administered with semaglutide

Treatments tested

AT673 low dose Drug

low dose
AT673 high dose Drug

high dose
Placebo Drug

matching placebo

Main thing measured	Body weight
Sponsor	Antag Therapeutics
Conditions studied	Adults With Overweight/Obesity and Type 2 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07724340 ↗